Fawell Stephen 4

What Happened

• Stephen Fawell, a director of C4 Therapeutics (CCCC), received a derivative award on June 24, 2026: an option covering 62,000 shares (reported at $0.00). This was a grant of an equity award — not an open-market purchase or a sale — and no cash was paid at grant.

Key Details

• Transaction date: 2026-06-24; Form 4 filed: 2026-06-26 (timely filing).
• Grant type: Derivative equity award (option) for 62,000 shares; reported price $0.00 (no cash paid at grant).
• Vesting/exercisability: The option vests and becomes exercisable in full upon the earlier of (i) June 24, 2027 and (ii) the next annual meeting of stockholders, subject to continued board service (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, tax withholding sale, or late filing in the provided data.

Context

• This is a standard director equity grant used for compensation/retention. Because it is a derivative option that vests in the future, it does not represent immediately tradable shares or an immediate cash transaction. Such grants are common and do not, by themselves, signal a resale or purchase intent.